Literature DB >> 27932119

Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation.

P Ramirez1, L Sáenz2, P A Cascales-Campos3, M R González Sánchez1, E Llàcer-Millán1, M I Sánchez-Lorencio4, E Díaz-Rubio5, V De La Orden6, B Mediero-Valeros6, J L Navarro7, B Revilla Nuin8, A Baroja-Mazo8, J A Noguera-Velasco4, B F Sánchez1, J de la Peña9, J A Pons-Miñano10, F Sánchez-Bueno1, R Robles-Campos1, P Parrilla1.   

Abstract

INTRODUCTION: The objectives of this study are the determination of the number of circulating tumor cells (CTCs), by means of the IsoFlux enrichment system (Fluxion Biosciences Inc, San Francisco, California, United States) in patients with hepatocellular carcinoma (HCC) in compliance with the Milan criteria and on the waiting list for hepatic transplantation, as well as the study of its relation with the of α-fetoprotein levels (AFP) and positron-emission tomography-computed tomography (PET-CT) findings. PATIENTS AND METHODS: An oncologycal evaluation with PET-CT, CTCs, and AFP was conducted in 24 consecutive patients with HCC eligible for orthotopic liver transplantation according to the Milan criteria. The diagnosis of HCC was made according to clinical, biological, and radiological findings.
RESULTS: We detected CTCs in peripheral blood in 21 of 24 patients (87.5%) before liver transplantation, with a mean number CTCs of 156 ± 370 (range, 2 to 1768) with statistically significant association between number of CTCs detected in peripheral blood and the time within the waiting list (P < .05), but not betwen AFP levels and standard uptake value and time to orthotopic liver transplantation (P > .05).
CONCLUSIONS: PET-TC, CTCs, and AFP levels could be an essential key for the correct management of the patients with HCC on the waiting list for liver transplantation. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27932119     DOI: 10.1016/j.transproceed.2016.07.035

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Orthotopic liver transplantation improves postoperative quality of life, survival rate and reduces recurrence rate in patients with liver cancer.

Authors:  Xia Zhang; Lizhi Lv; Zhixian Wu; Dongliang Li; Kun Zhang; Yonghai Peng
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

2.  VTX-1 Liquid Biopsy System for Fully-Automated and Label-Free Isolation of Circulating Tumor Cells with Automated Enumeration by BioView Platform.

Authors:  Elodie Sollier-Christen; Corinne Renier; Tal Kaplan; Elad Kfir; Steve C Crouse
Journal:  Cytometry A       Date:  2018-09-13       Impact factor: 4.355

Review 3.  Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.

Authors:  María Lola Espejo-Cruz; Sandra González-Rubio; Javier Zamora-Olaya; Víctor Amado-Torres; Rafael Alejandre; Marina Sánchez-Frías; Rubén Ciria; Manuel De la Mata; Manuel Rodríguez-Perálvarez; Gustavo Ferrín
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

4.  Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.

Authors:  Zhitao Chen; Tielong Wang; Chuanbao Chen; Xitao Hong; Jia Yu; Yihao Ma; Yiwen Guo; Changjun Huang; Xiaoshun He; Weiqiang Ju; Maogen Chen
Journal:  J Oncol       Date:  2021-10-19       Impact factor: 4.375

Review 5.  Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?

Authors:  Stéphanie Gonvers; Parissa Tabrizian; Emmanuel Melloul; Olivier Dormond; Myron Schwartz; Nicolas Demartines; Ismail Labgaa
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

6.  Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation.

Authors:  Víctor Amado; Sandra González-Rubio; Javier Zamora; Rafael Alejandre; María Lola Espejo-Cruz; Clara Linares; Marina Sánchez-Frías; Gema García-Jurado; José Luis Montero; Rubén Ciria; Manuel Rodríguez-Perálvarez; Gustavo Ferrín; Manuel De la Mata
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

7.  Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream).

Authors:  Antonio J Ruiz-Rodríguez; Maria P Molina-Vallejo; Inés Aznar-Peralta; Cristina González Puga; Inés Cañas García; Encarna González; Jose A Lorente; M Jose Serrano; M Carmen Garrido-Navas
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.